StrokeNews

Thursday, February 13, 2014

Negative endovascular therapy INSIDE THIS ISSUE Direct thrombin inhibitors offer trials offer patient mix guidance neuroprotection 3 Speakers examine emerging ICH ultiple randomized trials of endo- never be superior to IV alteplase,” said Tudor G. inefficiency of care. Delays occurred between treatment strategies 4 vascular therapy will be explored Jovin, MD, session co-moderator and associate presentation and brain imaging, imaging to during “Negative Random- professor of neurology and chief of the Stroke angiography and angiography to groin puncture. Enhance your career: Become a M ized Studies in Endovascular Division at the University of Pittsburgh. Streamlining and making the flow of patient Professional Member 5 Therapy for Acute Stroke: Can Different “One of the benefits of these trials is that they care more efficient may lead to shorter treatment Study Designs Lead to Different Results” at represent an excellent opportunity to learn about times and better outcomes, Jovin said. These 8:40–10:10 a.m. Thursday in Ballroom 20BC who is more and less likely to benefit from endo- issues will be the focus of “State-of-the-Art En- Exhibitor Resource Section 8 “During this symposium, we’ll discuss if vascular therapy … and develop future directions dovascular Technology and Faster Reperfusion these trials were negative because of the state of for endovascular therapy Times Would Improve Outcomes in Endovas- Poster Tours continue today 11 the field when conducted and if more positive trials,” Jovin said. cular Treated Patients,” presented by Brian T. outcomes are achievable with contemporary Pooja Khatri, MD, see endovascular, page 5 knowledge and technology, or if there is a fun- professor of neurology at damental reason why endovascular therapy will the University of Cincinnati Neuroscience Institute, is co-moderator. Session The trials have com- at-a-Glance Tudor G. Jovin, MD pared endovascular thera- pies such as intra-arterial thrombolysis, throm- Negative Randomized bectomy and thromboaspiration with intravenous Studies in Endovascular alteplase and other standard medical therapies in Therapy for Acute Stroke: patients with acute stroke. The trials have largely Can Different Study failed to demonstrate that endovascular therapy Designs Lead to Different is superior to conventional therapies, including Results IV alteplase. The studies also didn’t show that endovascular therapies are inferior. Thursday, 8:40–10:10 a.m. Thus, it is uncertain if the negative results are Ballroom 20BC attributable to trial design and execution, out- Co-moderators: Tudor G. Jovin, MD, and dated technology, lack of proper systems of care Pooja Khatri, MD and patient selection or to the actual therapies. ISC 2014 provides exceptional education and cutting-edge technology in stroke prevention, One key lesson from the trials is the diagnosis, treatment and rehabilitation.

Hypothermia promising Update on palliative care in stroke management therapeutic for stroke alliative care in stroke is unlike pal- Gregory Zipfel, MD, associate professor herapeutic hypothermia is an liative care in many other disease of neurosurgery and neurology at Washington Session accepted neuroprotective treat- states. Depending on the patient and University School of Medicine in St. Louis, is at-a-Glance ment for cardiac arrest, but the the severity of the stroke, palliative co-moderator of the symposium. P Stroke Palliative Care T potential for neuroprotection in care may be end-of-life care or it may be a respite Optimum stroke care is a multidisciplinary stroke is less widely recognized. That lack from symptoms that’s part of a longer-term care effort. The stroke team needs to recognize the Thursday, 3:30–5 p.m. of recognition is about program. Or care goals may factors that are unique to palliative care after Ballroom 20A to change. change as the patient’s condi- stroke, symptom management, roles for pal- Co-moderators: Gregory Zipfel, MD, and “Hypothermia is tion changes. liative care consultants, gaps in evidence and Richard Zorowitz, MD the most promising “Palliative care in stroke research, and the ways attitudes and beliefs neuroprotective strategy is one area that doesn’t have affect quality of life, said Zorowitz, associate that we know of,” said a lot of science to it,” said professor of physical medicine and rehabilita- and the family. The ultimate goal is to work Thomas Hemmen, MD, Richard Zorowitz, MD, tion at Johns Hopkins University School of with the patient, caregivers and family to make PhD, associate profes- co-moderator of “Stroke Pal- Medicine in Baltimore. decisions in a collaborative process that is con- Thomas Hemmen, Richard Zorowitz, sor of neuroscience and MD, PhD MD liative Care” at 3:30–5 p.m. “Palliative care should be part of a well- sistent with their values and preferences.” director of the Uni- Thursday in Ballroom 20A. coordinated healthcare environment that While feeding is a standard element in versity of California, San Diego Stroke “Palliative care clearly has a lot of art in practice. enables informed patients and caregivers,” he palliative care, neurological complications of Program in La Jolla. “This is not often It is important that we have a better understanding said. “Palliative care must also be responsive stroke can affect what might otherwise be a appreciated in the neurological community. of how to provide palliative care and the resources to health professionals so they can focus on fairly straightforward decision. Aspiration is a see hypothermia, page 10 that are needed to implement our decisions.” the disease process and get to know the patient common complication of feeding that needs a see palliative care, page 10 PAID ADVERTISEMENT

More Innovation. More Validation. Better Outcomes.

Solitaire™ 2 Revascularization Devicece

Delivering more to transform acute ischemic stroke treatment.

With more than 1,000 patients enrolled across MORE 6 different studies, the Solitaire™ 2 device is the RIGOROUSLY most extensively researched mechanical thrombectomy TESTED device available.1-6

In every study, patient outcomes improved across BETTER all Modified Rankin Scale, with up to 62% achieving NEUROLOGICAL 1-7 OUTCOMES mRS 0-2 at 90 days.

The Solitaire™ 2 device has been proven to offer the LOWEST lowest observed mortality rate in any significant MORTALITY prospective study of mechanical thrombectomy devices.1-7

REFERENCES 1. Pereira VM, Gralla J, Davalos A, et al. Prospective, multicenter, single-arm study of mechanical thrombectomy using Solitaire Flow Restoration in acute ischemic stroke. Stroke. 2013;44(10):2802-2807. 2. Saver JL, Jahan R, Levy EI, et al; SWIFT Trialists. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel- group, non-inferiority trial. Lancet. 2012;380(9849):1241-1249. 3. Jahan R, Liebeskind D, Nogueira R, et al; for SWIFT Investigators. Abstract 163: TICI success rates in SWIFT: comparison between randomized arms and correlation to 90 day neurologic outcome. Stroke. 2013;44:A163. 4. Dávalos A, Pereira VM, Chapot R, et al; Solitaire Group. Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke. Stroke. 2012;43(10):2699-2705. 5. Schroth G. Endovascular stroke therapy in Bern: 20 years of experience. Presented at: 12th Congress of the World Federation of Interventional and Therapeutic Neuroradiology; November 9–13, 2013; Buenos Aires, Argentina. 6. Nguyen T, Malisch T, Castonguay A, et al. O-004 Balloon guide catheter improves recanalisation, procedure time, and clinical outcomes with Solitaire in acute stroke: analysis of the NASA Registry. J NeuroIntervent Surg. 2013;5:A2-A3. 7. Nogueira RG, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of Learn more at large vessel occlusions in acute ischaemic stroke (TREVO 2): A randomised trial. Lancet. 2012:DOI:10.1016/ S0140-6736(12)61299-9. covidien.com/solitaire The Solitaire™ 2 Revascularization Device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. Indications, contraindications, warnings and instructions for use can be found on the product labeling supplied with each device. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. COVIDIEN, COVIDIEN with logo, and Covidien logo are US and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company. ©2014 Covidien. MK1027012014A strokeconference.org Thursday, February 13, 2014 StrokeNews 3

Direct thrombin inhibitors offer neuroprotection irect thrombin inhibitors are who achieved a complete and maintained argatroban, a direct thrombin inhibitor, has at among the newest potential Session state of recanalization when argatroban was least theoretical advantages in terms of how neuroprotective agents to arrive at-a-Glance added to standard of care intravenous tissue much edema develops in the hemorrhagic D on the clinical trial scene. And Direct Thrombin Inhibitors plasminogen activator treatment compared to setting.” while most of these agents are still in clinical patients who got t-PA alone. The future for direct thrombin inhibition development, promising results have left and Neuroprotection: An Studies in animal models looking at the in stroke is wide open, she said. The question neurologists eager for more data on their Unexpected Journey inflammatory reaction within the ischemic appears to be less about whether direct safety and efficacy. core have found that direct thrombin thrombin inhibitors will enter clinical use Thursday, 3:30–5 p.m. “We are still learning about the molecular Room 30A-D inhibition reduced inflammation. While than when the first agent will be approved. mechanisms of ischemia and which ones results are early, both the rationale and the “Any area that works on our own Co-moderators: Jaroslaw Arnowski, MD, might be targets for treatment,” said PhD, and Sheryl Martin-Schild, MD, PhD results to date are positive. natural processes to turn a negative event Sheryl Martin-Schild, MD, PhD, assistant “Hemorrhage is filled with thrombin,” into a process that can facilitate recovery professor and director of the stroke program Martin-Schild said. “We already know that is exciting,” Martin-Schild said. “We are at Tulane University Hospital and Clinic, said. Researchers didn’t expect thrombin to at least part of the perihematomal edema anticipating that there will be even more Tulane University School of Medicine in play a direct role in instigating injury during is actually related to inflammation. We can studies using these agents to treat not only New Orleans. “Thrombin inhibitors are ischemia and that thrombin can be targeted to reduce inflammation by targeting thrombin central occlusions but the actual parenchyma. promising because thrombin has recently been minimize ischemic damage. with an anti-thrombin agent. Something like It is getting close.” demonstrated to play an important role in the Multiple receptors play a role in platelet ischemic cascade, causing direct injury to the activation. One of the key families of neurovascular bundle.” receptors, protease-activated receptors, is We are still learning about the molecular mechanisms Martin-Schild will moderate a symposium activated in the presence of thrombin. of ischemia and which ones might be targets for on “Direct Thrombin Inhibitors and Direct thrombin inhibitors can prevent Neuroprotection: An Unexpected Journey” microthrombi from occluding smaller vessels treatment. Thrombin inhibitors are promising because at 3:30–5 p.m. Thursday in Room 30 A-D. downstream from the initial blockage. thrombin has recently been demonstrated to play an Her co-moderator is Jaroslaw Arnowski, MD, Thrombin inhibition can also limit the PhD, professor of neurology and vice chair for inflammatory component of ischemia. important role in the ischemic cascade, causing direct research at the University of Texas Medical One of the most promising direct thrombin injury to the neurovascular bundle. School in Houston. inhibitors, argatroban, is being studied as an Thrombin inhibition is not a new concept, adjunctive treatment to standard thrombolytic Sheryl Martin-Schild, MD, PhD but the apparent utility of thrombin inhibition therapy. Promising early stage studies showed in stroke has been a surprise, Martin-Schild a significantly higher proportion of patients ‘Blogging Stroke’ a hit with journal readers; Stroke StrokeNews continues as top venue for publishing research troke, an American Heart Associa- Health apps, with full content now limited to Thursday, February 13, 2014 tion/American Stroke Association member and non-member subscribers. To claim Reporting important new journal, celebrated the one-year access to the iPad editions of the journals to The Stroke News is produced for S anniversary of “Blogging Stroke” which you subscribe, visit ahajournals.org/site/ information from major meetings the American Heart Association/ (strokeblog.strokeahajour- misc/ipadapps.xhtml for in- will continue in the future. American Stroke Association’s nal.org). The blog highlights structions. JAHA — Journal International Stroke Conference by newly published studies in of the American Heart Marc Fisher, MD Ascend Integrated Media, LLC. the journal and fosters the Association is always acces- involvement of the younger sible for free. Yvette Ballantyne, MA members of the stroke com- The AHA Scientific At ahajournals.org, AHA/ASA members Senior Manager, munity. The blog features Statements and Guidelines have online access to full content, depending on International Stroke Conference reports from participants at for 2013, collectively pub- membership level. Anyone can access tables of scientific meetings, includ- lished in January as a free contents and article abstracts, sign up for elec- Amy Ciarochi ing the International Stroke iPad supplement, also in- tronic table of contents alerts and RSS feeds, and Corporate Promotions Manager Conference, and reported clude the AHA/ASA “Heart read Editor’s Picks. breaking news after presenta- Disease and Stroke Statistics Visit the AHA/ASA HeadQuarters (#241) or Anne Leonard tions of major trials at the — 2014 Update.” The Wolters Kluwer Health-Lippincott Williams & MPH, RN, CCRC, FAHA European Stroke Conference supplement is free through Wilkins booth (#427) in the Science & Technol- Science and Medicine Advisor in London in May 2013. any of the 11 AHA journal ogy Hall to check out the AHA journals’ apps “Reporting important new apps produced by Wolters and other new features; pick up a complimen- Roger Campbell information from major meetings will continue Kluwer Health. If you don’t have an iPad, you tary sample copy of any of the AHA’s five print Senior Editor/Writer in the future,” said Marc Fisher, MD, Stroke can access all AHA Statements and Guidelines at journals; and obtain information for authors, editor in chief. my.americanheart.org/statements. members and subscribers. ©2014 by the The Eigenfactor score and total number American Heart Association/ of citations published by the Journal Citation American Stroke Association Reports® ranked Stroke #2 in the clinical neurol- 7272 Greenville Avenue ogy and peripheral vascular disease subject Stroke quality campaign reaches major milestone Dallas, TX 75231 categories, attesting to the substantial academic his year marked a significant ac- patient outcomes. Nearly 1,500 hospitals 1-888-4-STROKE visibility of the journal (2012 Journal Citation complishment for the AHA/ASA’s across the country are now registered with Reports® [Thomson Reuters, 2013]). Target: Stroke quality improvement Target: Stroke, and about 400 of those have www.strokeassociation.org Stroke webinars remain a staple of the jour- T campaign to get faster clot-busting achieved Honor Roll status for consistently nal, presenting high-impact advances in the cere- treatment to ischemic stroke patients. The meeting the best practice criteria of the brovascular field to researchers and clinicians campaign, launched in February 2010, has campaign. AHA/ASA will recognize these alike. Visit stroke.ahajournals.org/site/misc/ reached its goal of ensuring at least 50 per- hospitals during special events held at the Stroke_Webinars.xhtml for more information cent of eligible stroke patients treated nation- International Stroke Conference this week. Nursing Symposium: February 11 Sessions: February 12–13 and to view the most recent archived webinars. wide receive IV rtPA in 60 minutes or less. Find Target: Stroke hospitals near you at Exhibits: February 12–13 AHA journals’ apps are available as free Target: Stroke provides health care pro- heart.org/myhealthcare. Learn more about Honolulu, Hawaii downloads at the iTunes App Store, including fessionals with 10 best practice strategies for the campaign at strokeassociation.org/ strokeconference.org free sample issues for each journal. The free trial reducing door-to-needle times aimed at better targetstroke. periods have expired for the Wolters Kluwer 4 StrokeNews Thursday, February 13, 2014 strokeconference.org

Speakers examine emerging ICH treatment strategies

lood pressure reduction, minimally ology of ICH and review blood pressure reduc- comparisons of acute surgical clot removal and invasive surgery and neurosurgical tion and other potential management strategies,” medications.” Session at-a-Glance intervention — and other medical said Robert Loch Macdonald, MD, PhD, co- In the randomized INTERACT-2 trial, B and surgical strategies for managing moderator of the symposium from St. Michael’s researchers found intensive blood pressure Acute Management of intracerebral hemorrhage Hospital University of lowering was not associated with statistically ICH: Blood Pressure — are the focus of “Acute Toronto. “We’ll discuss significant reductions in death or severe dis- Management of ICH: pathophysiologic features ability. However, they found a trend suggesting Lowering, Surgery and Blood Pressure Lower- of ICH that may impact the blood pressure reduction improves secondary Future Directions ing, Surgery and Future efficacy of blood pressure endpoints. Thursday, 1:30–3 p.m. Directions” at 1:30–3 p.m. reduction, such as whether “One of the trial’s limitations was that the Room 30A-D Thursday in Room 30A-D. BP reduction increases the time needed to reduce patients’ blood pressure to “This session will focus risk of brain injury around desired levels was too long,” said Joshua Gold- Co-moderators: Robert Loch Macdonald, Robert Loch Joshua Goldstein, MD, and Joshua Goldstein, MD, PhD on the general pathophysi- Macdonald, MD MD, PhD the hematoma, as well as stein, MD, PhD, co-moderator of the symposium

and associate professor at Harvard Medical School in Boston. Craig Anderson, MD, PhD, professor of stroke medicine and clinical neuroscience at the University of Sydney, will present “Subgroup Analyses of the INTERACT2 Trial.” David Mendelow, MD, professor of neurosur- gery at Newcastle University, Newcastle in Tyne, England, will present “STICH II: Outcomes from the Surgical Trial of Lobar ICH.” STICH II com- pared acute surgical hematoma evacuation with medical therapy among patients with superficial lobar stroke. Sail Away With Savings on “Dr. Mendelow’s co-investigator, Barbara Gregson, PhD, is likely to discuss issues in the ™ trial’s execution — such as the large number of Stroke OnDemand Premium patients randomized to medical treatment who crossed over to surgery and delays to treatment — that may have affected results,” Goldstein said. Highlights: Gregson, principal research associate at the Institute of Neuroscience, Newcastle University, Convenient Online & Mobile Viewing on your iPad, iPhone and in Newcastle Upon Tyne, United Kindom, will Android Device discuss “Does Craniotomy Reduce the Volume of ICH-evidence from STICH II.” Downloadable PDFs of Presenter Slides and Audio MP3s Daniel F. Hanley, MD, PhD, professor of neu- rology, anesthesiology, critical care medicine and Includes State-of-the-Science Stroke Nursing Symposium & Pre- neurological surgery at Johns Hopkins University Conference Symposium: Stroke in the Real World: Emergency School of Medicine in Baltimore, will present “Innovative Approaches Utilizing Minimally Stroke Care 2014 Invasive Surgery plus Pharmacotherapy.” Portable DVD-ROM for On-the-Go Access* “Ongoing studies are working on the idea that surgery itself might cause some brain damage,” Purchase today in the Hall F Lobby Macdonald said. “So, if you can do the operation minimally invasively and slowly remove the he- matoma with appropriate medications, you might *DVD-ROM ships 8 weeks after the meeting. Only presentations that have been approved by the speakers will be included. Pricing excludes shipping and handling. Discounts do not apply to the general or professional improve outcomes compared to no surgery.” associate membership tiers. This session is important to anyone involved in managing ICH patients, including neurointen- sivists, neurosurgeons and nurses, he said.

Save Claim your $100 CME/CE credit You have two ways to complete your Onsite conference evaluation and claim your CME/CE credits for the conference, pre-conference symposia and/or nursing symposium. • Stop by the Communication Center, which is located in the Hall F Lobby, Ground Level of the San Diego Convention Center. • Visit learn.heart.org from any computer with Internet connection.

International attendees may obtain an strokeondemand.org attendance verification form at one of the self-service terminals in Registration. strokeconference.org Thursday, February 13, 2014 StrokeNews 5

Speakers examine emerging ICH treatment strategies Symposium to shed light on pediatric stroke he latest cutting-edge research and in the pediatrics and at its utility in the the role of inflammation.” strategies for neuroprotection of the neurology departments Hypothermia has developing brain. Susan Vannucci, research professor of ischemic brain in neonates, children and at Loma Linda (Calif.) been around for Interest was stirred neuroscience in pediatrics at Weill Cornell T adolescents is the focus of “Protecting University School of by two clinical trials Medical College in New York, will focus on the Ischemic Neonatal Brain: What Can We Do Medicine, is co-mod- decades and is showing benefit in current research in the inflammatory cascade Better?” at 7–8:30 a.m. Thursday in Room 33. erator. used in adult stroke children with diffuse triggered by stroke and targeting inflammation “Scientists are looking at many strategies for Mary Stenzel-Poore, ischemic injury. It is for intervention in “Inflammation as a Target reducing the damage resulting from ischemic in- PhD, senior associate patients. Only unclear if it will also for Neuroprotection.” jury in the developing brain,” said Rand Askalan, dean for research and recently have scientists looked at be beneficial in babies Michael Johnston, MD, director of the MD, PhD, co-moderator of the symposium and professor and chair of with the focal injuries Neuroscience Laboratory at Kennedy Krieger assistant professor of pediatrics at the University molecular microbiology its utility in the developing brain. typical of stroke.” Institute in Baltimore, will discuss other of Toronto. and immunology at Or- Jerome Yager, neuroprotective strategies in clinical use, such Stephen Ashwal, MD, distinguished professor egon Health & Science Rand Askalan, MD MD, professor and as seizure, blood pressure and fever reduction, University in Portland, head of the pediatric in “Neuroprotection of the Ischemic Brain will kick off the sympo- neurosciences at the Developing Brain: How Close Are We to the Session sium with a discussion University of Alberta Bedside?” at-a-Glance on “Protecting the Ischemic Brain: Lessons to be in Canada, will focus on hypothermia as a The symposium is also dedicated to “in- Protecting the Ischemic Learned from the Adult Brain.” Stenzel-Poore treatment for focal injuries and strategies for creasing awareness about stroke in children,” will discuss reasons why neuroprotective therapy improving hypothermia in “Hypothermia: Can Askalan said. “Although awareness of pediatric Neonatal Brain: What Can has not reached the bedside of adults with strokes We Push the Boundaries?” stroke is better than it was several years ago, We Do Better? despite decades of research. Another major area of emerging research is there are still people in the medical field who One hot topic at this year’s symposium will the role of inflammation in stroke. are surprised that children suffer strokes. Thursday, 7–8:30 a.m. Room 33 be hypothermia, Askalan said. “Stroke is not just about cell death,” Askalan “The ISC has increased the presence of “Hypothermia has been around for decades said. “Inflammation is an important component pediatric stroke sessions in the program, and Co-moderators: Stephen Ashwal, MD, and is used in adult stroke patients,” she of ischemic injury. You cannot think about we hope this symposium will help to continue and Rand Askalan, MD said. “Only recently have scientists looked neuroprotective strategies without considering to raise awareness.”

Thanks to supporters of ISC 2014 Enhance your career: Become a Professional Member hether you are just launching resources provided by the AHA and organized Visit our staff at HeadQuarters, Booth 241 in he American Stroke Association your career and looking to grow in themed communities corresponding to the Science & Technology Hall (open at 10 a.m.- would like to acknowledge the in your specialty or you are a AHA councils 4 p.m. Thursday), or go to my.americanheart. following company for its gener- W Fellow of the American Heart • Opportunities to apply for and receive council org/membership to learn more about the ben- T ous educational grant in support Association interested in broadening your leader- awards efits of joining our network of more than 30,000 of the International Stroke Conference ship opportunities, Professional Membership • Connections quarterly newsletter with Members. 2014 education programming: with the American Heart Association/American council-specific information • Covidien Stroke Association offers benefits tailored to you. • Online version of the Join during the International Stroke Confer- Journal of the Ameri- The American Stroke Association is ence and receive career-advancing benefits, can Heart Association, grateful for the continued support and including: a savings of $500 in generosity of the following companies: • Waived fees for research grant applications publication fees • Genentech, a Member of the Roche Group • Priority registration and housing at Interna- • Free access to Stroke • Wolters Kluwer Health Medical Re- tional Stroke Conference 2015 and Scientific OnDemand™ member- search Sessions 2014 only products which • Notification about AHA and national affiliate includes PDF slides research funding opportunities and audio MP3 files of • Notices about upcoming AHA scientific presentations. Also dis- conferences and requests for abstracts counts for Stroke On- ISC 2015 and Nursing • Opportunities to volunteer to be a peer Demand™ Premium. Symposium 2015 Call reviewer • Networking with peers for Science • Unlimited access to the AHA’s Professional • Much more Online Network Also, receive up to $500 off Join or renew on site and receive either a Session Ideas • Access to the AHA Learning Library, a Web ISC 2015 registration rates and similar savings canvas duffle bag or a fleece jacket (while supplies last). Each bears the AHA/ASA logo. Suggested Session Submitter Opened: portal to a broad spectrum of professional at other AHA scientific conferences. Monday, Feb. 10, 2014 Suggested Session Submitter Closes: Monday, March 10, 2014 endovascular t-PA? Would Any Other Trial Design Have Led to port its use,” Jovin said. “That is a big problem Abstracts continued from page 1 Different Results?” The session will highlight the because if we think that endovascular therapy Submission Opens: Wednesday, May 21, fact that contrary to what many believed IV tPA is should become standard of care, we need to 2014 Jankowitz, MD, assistant professor of neurologi- beneficial for stroke due to middle cerebral artery generate this type of data. To do that, we need to Submission Closes: Tuesday, Aug. 12, 2014 cal surgery and co-director of neuroendovascular occlusion. It will analyze what, if any, conditions be able and willing to randomize every eligible therapy at the University of Pittsburgh. will need to be satisfied to obtain better outcomes patient and not pick and choose patients where Late-Breaking Science and Ongoing Another controversy surrounding endovas- with IA therapy compared to IV tPA. the feeling of equipoise is most pronounced. Clinical Trials Abstracts cular therapy trials is defining the population of Antoni Davalos, MD, PhD, professor and This was a problem in many previous trials. Submission Opens: Wednesday, Oct. 8, 2014 patients mostly likely to benefit. This is the fo- head of the Department of Neurosciences at These failed trials provide a good impetuous to Submission Closes: Wednesday, Nov. 5, 2014 cus of “Better Patient Selection Would Improve Hospital Universitari Germans Trias i Pujol, in randomize every eligible patient. Outcomes in Endovascular Treated Patients,” Barcelona, Spain, will discuss “Endovascular “To be able to accomplish that, some say The link to submit abstracts and/or session presented by Raul G. Nogueira, MD, director of Stroke Therapy Outside Clinical Trials: Should that treatment outside of trials should not be ideas can be found at strokeconference. the Neuroendovascular Division, Marcus Stroke We Still Offer It?” The talk will focus on the offered. This concept is controversial because org/submitscience on the appropriate & Neuroscience Center in Atlanta. real-world use of endovascular therapies and the others contend that under these circumstances, date above. Start planning now for the Gregory W. Albers, MD, professor of importance of including every eligible patient in patients who do not meet inclusion criteria will International Stroke Conference 2015, neurology and neurological sciences at Stanford clinical trials. be denied potentially beneficial therapy. How to Feb. 11–13 in Nashville, Tenn. University School of Medicine in Palo Alto, “Although centers are offering endovascular approach this controversial issue is the focus of Calif., will present, “Can Endovascular Best IV procedures, there is no level I evidence to sup- Davalos’s talk.” PAID ADVERTISEMENT

Transforming Stroke Treatment Through Clinical Science

Covidien is dedicated to continuously advancing the vascular field with breakthrough evidence-based technologies.

Setting the clinical standard for mechanical thrombectomy: Powerful prevention delivering proven results: Solitaire™ 2 Revascularization Device Kendall SCD™ System

Rigorously Tested: With more than 1,000 patients Proximal DVT Reduction: A multicenter, randomized enrolled across 6 different studies, the Solitaire™ 2 controlled trial of 2,876 patients across the UK (CLOTS 3) device is the most extensively researched mechanical showed a statistically significant 29.9% reduction in thrombectomy device available.1-6 Proximal DVT.8 Visit us at booth #535 Better Neurological Outcomes: In every study, patient Reduced Risk of Mortality: The CLOTS 3 Study additionally during ISC to learn outcomes improved across the Modified Rankin Scale, with showed a 14.0% reduction in mortality risk. Used regularly, up to 62% achieving mRS 0–2 at 90 days.1-7 the device could potentially save 10,000 lives how Covidien is each year in the US alone.8 committed to stroke Lowest Mortality: The Solitaire™ 2 device has been treatment through proven to offer the lowest observed mortality rate in any significant prospective study of mechanical clinical evidence. thrombectomy devices.1-7

REFERENCES 1. Pereira VM, Gralla J, Davalos A, et al. Prospective, multicenter, single-arm study of mechanical thrombectomy using Solitaire Flow Restoration in acute ischemic stroke. Stroke. 2013;44(10):2802-2807. 2. Saver JL, Jahan R, Levy EI, et al; SWIFT Trialists. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380(9849):1241-1249. 3. Jahan R, Liebeskind D, Nogueira R, et al; for SWIFT Investigators. Abstract 163: TICI success rates in SWIFT: comparison between randomized arms and correlation to 90 day neurologic outcome. Stroke. 2013;44:A163. 4. Dávalos A, Pereira VM, Chapot R, et al; Solitaire Group. Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke. Stroke. 2012;43(10):2699-2705. 5. Schroth G. Endovascular stroke therapy in Bern: 20 years of INDICATIONS experience. Presented at: 12th Congress of the World Federation of Interventional and Therapeutic Neuroradiology; November 9–13, 2013; The Solitaire™ 2 Revascularization Device is intended for use as adjunctive therapy to improve neurological outcomes and decrease mortality in patients experiencing an acute ischemic stroke in large intracranial Buenos Aires, Argentina. 6. Nguyen T, Malisch T, Castonguay A, et al. O-004 Balloon guide catheter improves recanalisation, procedure vessels within 6 hours of symptom onset. time, and clinical outcomes with Solitaire in acute stroke: analysis of the NASA Registry. J NeuroIntervent Surg. 2013;5:A2-A3. 7. Nogueira The Solitaire™ 2 Revascularization Device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients RG, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): A who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. Indications, contraindications, warnings and instructions for use can be found on the randomised trial. Lancet. 2012:DOI:10.1016/ S0140-6736(12)61299-9. 8. Dennis M, Sandercock P, Reid J, et al. Effectiveness of intermittent product labeling supplied with each device. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial Lancet. 2013;382(9891):516-524. COVIDIEN, COVIDIEN with logo, and Covidien logo are US and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company. ©2014 Covidien. MK1028012014A PAID ADVERTISEMENT

Transforming Stroke Treatment Through Clinical Science

Covidien is dedicated to continuously advancing the vascular field with breakthrough evidence-based technologies.

Setting the clinical standard for mechanical thrombectomy: Powerful prevention delivering proven results: Solitaire™ 2 Revascularization Device Kendall SCD™ System

Rigorously Tested: With more than 1,000 patients Proximal DVT Reduction: A multicenter, randomized enrolled across 6 different studies, the Solitaire™ 2 controlled trial of 2,876 patients across the UK (CLOTS 3) device is the most extensively researched mechanical showed a statistically significant 29.9% reduction in thrombectomy device available.1-6 Proximal DVT.8 Visit us at booth #535 Better Neurological Outcomes: In every study, patient Reduced Risk of Mortality: The CLOTS 3 Study additionally during ISC to learn outcomes improved across the Modified Rankin Scale, with showed a 14.0% reduction in mortality risk. Used regularly, up to 62% achieving mRS 0–2 at 90 days.1-7 the device could potentially save 10,000 lives how Covidien is each year in the US alone.8 committed to stroke Lowest Mortality: The Solitaire™ 2 device has been treatment through proven to offer the lowest observed mortality rate in any significant prospective study of mechanical clinical evidence. thrombectomy devices.1-7

REFERENCES 1. Pereira VM, Gralla J, Davalos A, et al. Prospective, multicenter, single-arm study of mechanical thrombectomy using Solitaire Flow Restoration in acute ischemic stroke. Stroke. 2013;44(10):2802-2807. 2. Saver JL, Jahan R, Levy EI, et al; SWIFT Trialists. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380(9849):1241-1249. 3. Jahan R, Liebeskind D, Nogueira R, et al; for SWIFT Investigators. Abstract 163: TICI success rates in SWIFT: comparison between randomized arms and correlation to 90 day neurologic outcome. Stroke. 2013;44:A163. 4. Dávalos A, Pereira VM, Chapot R, et al; Solitaire Group. Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke. Stroke. 2012;43(10):2699-2705. 5. Schroth G. Endovascular stroke therapy in Bern: 20 years of INDICATIONS experience. Presented at: 12th Congress of the World Federation of Interventional and Therapeutic Neuroradiology; November 9–13, 2013; The Solitaire™ 2 Revascularization Device is intended for use as adjunctive therapy to improve neurological outcomes and decrease mortality in patients experiencing an acute ischemic stroke in large intracranial Buenos Aires, Argentina. 6. Nguyen T, Malisch T, Castonguay A, et al. O-004 Balloon guide catheter improves recanalisation, procedure vessels within 6 hours of symptom onset. time, and clinical outcomes with Solitaire in acute stroke: analysis of the NASA Registry. J NeuroIntervent Surg. 2013;5:A2-A3. 7. Nogueira The Solitaire™ 2 Revascularization Device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients RG, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): A who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. Indications, contraindications, warnings and instructions for use can be found on the randomised trial. Lancet. 2012:DOI:10.1016/ S0140-6736(12)61299-9. 8. Dennis M, Sandercock P, Reid J, et al. Effectiveness of intermittent product labeling supplied with each device. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial Lancet. 2013;382(9891):516-524. COVIDIEN, COVIDIEN with logo, and Covidien logo are US and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company. ©2014 Covidien. MK1028012014A 8 StrokeNews EXHIBITOR PRODUCT & RESOURCE SECTION

Science & Technology Exhibit Hall: Explore this must-see destination

he Science & Technology Exhibit Hall returns to ISC 2014 with a unique blend of innovative equipment, Join us in AHA/ASA HeadQuarters, supplies and services. Nowhere else can you take in Booth 241 T such offerings at one place at one time. Visit with representatives from more than 75 companies Thursday at 10 a.m.-4 p.m. on Thursday. Any time you need to get 10 –11 a.m. connected, just stop by one of the Wi-Fi hotspots, located in AFIB Jeopardy! the Restaurant, Booth 253, and Charging Station, Booth 525. 11:10 –11:30 a.m. Be sure to check out the American Heart Association/ Advocacy — A Year of Advocacy Successes: American Stroke Association’s HeadQuarters, located in You’re the Cure Booth 241, where you can: • Get information on the latest AHA/ASA initiatives, 11:35 a.m.–12:15 p.m. including Advocate: You’re the Cure, American Stroke Education On-demand: Learn.Heart.org Association, Charitable Estate Planning, Connected Heart Michelle Bruns, AHA Professional Education Health, Emergency Cardiovascular Care CPR & First 12:20–1:20 p.m. Aid, Focus on Quality, Health eHeart Study, Multicultural Stroke Journal webinar: Stroke Genetics Markets Power To End Stroke, Patient Education/Online Martin Dichgans, MD Patient Education, Professional Education and Scientific Publications. 1:30–2 p.m. Stroke OnDemand™ Premium Product demonstration • Network with your colleagues in the relaxing atmosphere of Learn all of the features of this educational tool. the Member Circle and power up your smartphone, iPad and Diane Perrino, Astute Technology other electronic devices (for AHA/ASA Members only). • Take in several presentations in the Theater (see box). Visit Check out the many must-see destinations in the Science & Booth 241 for a detailed schedule. Technology Exhibit Hall. EXHIBITOR LIST

ACRM | American Congress American Board of Avanir Pharmaceuticals 115 Corazon, Inc. 425 Ekso Bionics 121 GlobalMed 644 of Rehabilitation Neuroscience Nursing 20 Enterprise, ste 200 5000 McKnight Road, Suite 1414 Harbour Way S. 15020 North 74th Street Medicine 316 (ABNN) 242 Aliso Viejo, CA 92656 300 Richmond , Ca 94804 Scottsdale, Arizona 85260 11654 Plaza America Drive, Suite 535 8735 W. Higgins Road, Suite 300 [email protected] Pittsburgh, PA 15237 (510) 984-1761 [email protected] Reston, VA 20190 Chicago, IL 60631 web: www.avanirmedinfo.com/ (412) 364-8200 WEB: eksobionics.com web: www.globalmed.com (703) 574-5845 (847) 375-4733 Avanir Pharmaceuticals, Inc. is a biopharmaceu- WEB: corazoninc.com Ekso GT™ is a robotic exoskeleton, or wear- GlobalMed develops integrated telemedicine [email protected] [email protected] tical company focused on acquiring, developing Corazon is a national leader in program develop- able robot, that’s redefining rehabilitation for solutions. The company’s array of connected WEB: ACRM.org WEB: ABNNcertification.org and commercializing novel therapeutic products ment for Neuroscience, Cardiovascular, and individuals living with the consequences of medical devices and patient data workflow Delivering cutting-edge, evidence-based con- The American Board of Neuroscience Nursing for the treatment of central nervous system Orthopedic service lines, offering Consulting, stroke, spinal cord injury, and other neurological systems enable complete patient encounters, tent, the 91st Annual ACRM Conference, Prog- (ABNN) is the independent, not-for-profit cor- disorders. Software, Recruitment, and Interim Manage- conditions. Ekso enables individuals with any worldwide. Our mission is to transform health- ress in Rehabilitation Research, is the largest poration established to design, implement, and ment Solutions. We provide the strategic, clini- amount of lower extremity weakness to walk care globally, by developing integrated, secure interdisciplinary conference for rehabilitation re- evaluate a certification program for professional Boehringer Ingelheim cal, operational, market, and financial expertise over ground with a natural, full weight bearing and efficient care delivery systems that improve search. Non-stop content for brain injury, spinal nurses involved in the specialty practice of neu- Pharmaceuticals, Inc. 125 necessary to develop a truly outstanding and reciprocal gait. access and quality of care while eliminating cord injury, stroke, neurodegenerative diseases, roscience nursing and its sub-specialties. The 900 Ridgebury Road specialty program, regardless of your existing unnecessary costs. scope of services. Encore Medical pain, and cancer rehabilitation. CME/CEU credit CNRN and SCRN certification and recertification Ridgefield, CT 06877 H. Lundbeck A/S 135 in nine disciplines. 7 – 11 October 2014 Toronto, programs are overseen by ABNN. WEB: us.boehringer-ingelheim.com Education — Canada. www.ACRMconference.org. Boehringer Ingelheim Pharmaceuticals, Inc., Cornerstone Best of ISC 227 Ottiliavej 9 Apex Innovations 510 the US subsidiary of Boehringer Ingelheim, Therapeutics 517 1937 Cedardale Ave. Valby DK2500 Denmark AHA Charging Station 525 3909 Ambassador Caffery Parkway headquartered in Germany, operates globally 1255 Crescent Green Drive Baton Rouge, LA 70808 (453) 630-1311 Building K with more than 44,000 employees. The com- Suite 250 (410) 703-3500 WEB: lundbeck.com AHA Science News 211 Lafayette, LA 70503 pany is committed to researching, developing, Cary, NC 27518 [email protected] H. Lundbeck A/S is an international pharmaceu- tical company highly committed to improving (866) 294-4599 manufacturing and marketing novel products of (888) 466-6505 WEB: encoremeded.com the quality of life for people suffering from brain AHA/ASA [email protected] high therapeutic value for human and veterinary [email protected] Encore organizes “Best of International Stroke disorders, and is currently developing des- HeadQuarters 241 WEB: apexinnovations.com medicine. Visit http://us.boehringer-ingelheim. WEB: crtx.com Conference” live events in countries around moteplase for treatment of patients with acute 7272 Greenville Ave Hemispheres®-Stroke Competency Series - The com, Follow us on twitter at @boehringerus. Cornerstone Therapeutics is a specialty pharma- the world. Industry supports the educational ischaemic stroke. The booth will contain relevant Dallas, TX 75231 best just got better! Multiple cost-effective ceutical company focused on commercializing events for specialists in their own country to- publications and a coffee service. web: myamericanheart.org courses with updated content and practice Boston AF Symposium 220 products for hospital and adjacent specialty gether to learn the current research and treat- Be sure to check out the American Heart guidelines. Amazing graphics, search, book- markets. Cornerstone currently promotes four ments in stroke. Visit Encore to bring a meeting Association/American Stroke Association’s mark, key questions, Intelligent Interactivity®, The Brain Aneurysm products; PERTZYE® (pancrelipase) Delayed- to your region. Hocoma USA 434 HeadQuarters, located in Booth 241, where and other features to enhance the learning Foundation 324 Release Capsules, BETHKIS® (Tobramycin In- 77 Accord Park Drive D-1 you can: experience. Includes testing, CE credit, report- 269 Hanover St. halation Solution), CUROSURF® (poractant alfa) Enos, Tardis, Norwell, MA 02061 • Get information on the latest AHA/ASA initia- ing, benchmarking, FREE NIHSS. Call us and Building 3 Intratracheal Suspension and CARDENE®IV Tich -2 Trials 313 (480) 213-4407 tives: American Stroke Association, Focus get ready to be impressed! Hanover, MA 02339 (nicardipine hydrochloride) Premixed Injection. Division of Clinical Neuroscience, WEB: hocoma.com on Quality, Power To End Stroke, Patient Our booth will consist of 2 robotic rehabilitation (781) 826-5556 For information on Cornerstone or our products, Stroke, Clinical Sciences Building Education devices that serve as key early rehabilitation [email protected] visit www.crtx.com. • Network with your colleagues in the Member Asahi Intecc USA, Inc. 119 City Hospital, Hucknall Road therapy for patients who have suffered a stroke WEB: bafound.org Circles Nottingham, Nottinghamshire NG51PB or other neurological illness. The Erigo device 2500 Red Hill Ave. Suite The Brain Aneurysm Foundation: The nation’s Covidien 535 • Theater United Kingdom focuses on early mobilization and verticalization 210 PREMIERE non-profit organization solely dedi- 9775 Toledo Way (115) 823-1770 of a patient. The Lokomat is a robotic gait train- Santa Ana, CA 92705 cated to providing critical awareness, education, Irvine, CA 92618 [email protected] ing device that retrains walking. Allergan 235 (949) 756-8901 support and research funding to reduce the (508) 261-8000 WEB: nottingham.ac.uk/research/groups/stroke/ 2525 Dupont Drive web: asahi-inteccusa-medical.com incidence of brain aneurysm ruptures. WEB: covidien.com index.aspx Irvine, CA 92612 Asahi Intecc is a medical device company Covidien is a leading global healthcare products Hospital Corporation Efficacy of Nitric Oxide in Stroke (ENOS) Trial, (714) 246-4500 focused on delivering clinically unique devices company, creating innovative medical solutions of America (HCA) 237 used in vascular procedures by interventional Cardionet, a testing efficacy of transdermal glyceryl trinitrate WEB: allergan.com for better patient outcomes. With unmatched 3 Maryland Farms nuerologists, neurosurgeons, interventional BioTelemetry Company 320 for 7 days. Triple Antiplatelets for Reducing Allergan is a multi-specialty health care collaboration across arterial and venous to neu- Suite 250 cardiologists, and interventional radiologists. 1000 Cedar Hollow Road Dependency after Ischaemic Stroke (TARDIS); company established over 60 years ago with a Asahi will leverage its four core competencies rovascular, Covidien Vascular Therapies offers Suite 102 testing intensive antiplatelet vs guideline Brentwood, TN 37027 commitment to uncovering the best of science to develop device-based solutions targeting comprehensive solutions to help more physi- [email protected] specific niches where Asahi can achieve a Malvern, PA 19355 therapy with aspirin, dipyradamole, clopidogrel. and helping people. With approximately 11,400 cians deliver optimal patient care, worldwide. WEB: PracticeWithUs.com market leading position. (610) 729-7000 Tranexamic acid for hyperacute primary IntraCe- employees worldwide, we are committed to Visit www.covidien.com. HCA owns and operates 167 healthcare facilities WEB: cardionet.com rebral Haemorrhage (TICH-2); tranexamic acid in discovering new therapies to treat unmet medi- in 20 states with opportunities coast to coast. Asubio CardioNet, a BioTelemetry company, is the primary intracerebral haemorrhage. cal needs in eye care, neurosciences, medical DNV GL — Healthcare HCA was one of the nation’s first hospital world’s leading supplier of Mobile Cardiac dermatology, and urology. APC55PQ14 Pharmaceuticals, Inc. 549 companies. We are committed to the care and Outpatient Telemetry™ (MCOT™) and provides Inc. 420 FUJIFILM Corporation 514 399 Thornall St. improvement of human life. We strive to deliver next-generation ambulatory cardiac monitoring 400 Techne Center Drive 419 W. Ave. Edison, NJ 08837 quality healthcare that meets the needs of the service with beat-to-beat, real-time analysis, Suite 100 (201) 368-5025 Stamford, CT 06902 communities we serve. [email protected] automatic arrhythmia detection and wireless Milford, OH 45150 (203) 324-2000 WEB: asubio.com ECG transmission. Visit cardionet.com (866) 523-6842 [email protected] [email protected] INSTOR 512 Booth #549 - Asubio Pharmaceuticals, Inc. is WEB: fujifilmusa.com/products/medical P.O. Box 531958 Centura Health WEB: dnvglhealthcare.com FUJIFILM Corporation is a leading provider of an early stage clinical development company New Orleans, LA 70153 focusing on adding value to the novel new Physician Group 212 DNV GL - Healthcare is the leading accreditor diagnostic imaging products and medical infor- (877) 446-7867 chemical entities and biologics disovered in its 10333 E. Dry Creek Road of US hospitals integrating ISO 9001 quality matics solutions to meet the needs of healthcare [email protected] parent’s research facilities in Japan. Asubio Suite 100 compliance with the Medicare Conditions facilities today and well into the future. From of Participation. Our NIAHO® accreditation ® WEB: strokeregistry.org is developing novel compounds to treat acute Englewood, CO 80112 digital x-ray systems, to the Synapse brand ISC 2014 platform helps you achieve constant readiness, of PACS, RIS and cardiovascular products, INSTOR is a complete solution for data docu- brain disorders. Clinical trial to start late 2014. (303) 643-0933 eliminate survey shock, and inspire your staff. Fujifilm has ideal products for any size imaging mentation and analysis designed specifically to [email protected] environment. improve your stroke program and patient out- Unofficial WEB: centurahealth.org AtriCure, Inc. 518 DWL USA, INC. 616 comes with less work. INSTOR fulfills all man- Centura Health is a large hospital system 30320 Rancho Viejo Road, dates from the Joint Commission and all Neuro 6217 Centre Park Drive located in Colorado and Western Kansas. Genentech, A Member of Suite 105 Medical Societies as concerning Performance Satellite Events West Chester, Ohio 45069 the Roche Group 411, 412 Measures for Emergency Treatment of acute (513) 755-4100 CommuniCare San Juan Capistrano, Ca 1 DNA Way ischemic stroke, automatically and instantly. [email protected] Technology 521 92675 South San Francisco, CA 94080 Thursday WEB: atricure.com P.O. Box 895 (888) 757-5351 (650) 225-1000 InTouch Health 435 AtriCure is intent on reducing the global Afib Bozeman, MT 59771 [email protected] WEB: gene.com 6330 Hollister Ave. WEB: dwl.us Considered the founder of the biotechnology 6:30 p.m. epidemic and healing the lives of those affected (877) 903-5642 Santa Barbara, CA 93117 At DWL, we have worked to perfect the tran- industry, Genentech has been delivering on through clinical science, education and innova- CommuniCare Technology (805) 562-8686 scranial Doppler for many years. Where others the promise of biotechnology for more than Registration tion. We are a leading Afib solutions partner pioneered mHealth apps, called WEB: intouchhealth.com have diversified, we have not. With a highly 30 years, using human genetic information with the only FDA-approved surgical treatment STOP STEMI, STOP Stroke, and STOP Sepsis InTouch Health’s Remote Presence telemedicine specialized international team of experts, we to discover, develop, manufacture and com- 7:15–8:30 p.m. for Afib and most widely implanted occlusion (the “STOP Apps”) that transform how people solution enables physicians to more easily and continuously work to make our Doppler systems mercialize medicines for patients with serious or device for left atrial appendage management. coordinate critical care. Without mobile technol- frequently consult and round on hospital- more efficient and user friendly. We’re doing life-threatening medical conditions. Update on Blood Pressure ogy, healthcare teams are not as efficient or based patients thereby improving throughput, what we do best, see us today! Management responsive in treating people experiencing efficiency and quality of care. Stroke specialists Aurora Health Care 223 stroke, sepsis, and STEMI. When time is tissue, Edge Therapeutics, can access a range of FDA-cleared devices to 3305 W. Forest Home Ave. every second counts. facilitate identification of stroke symptoms and San Diego Marriott Marquis Inc. 315 offer patients the most advanced care available. Milwaukee, WI 53215 200 Connell Drive Suite 1600 & Marina, San Diego (800) 307-7497 Berkeley Heights, NJ 07922 [email protected] (800) 208-3343 Ballroom B WEB: Aurora.org/Doctor [email protected] Aurora Health Care is a Wisconsin-based health WEB: edgetherapeutics.com Sponsored and supported care system and a nationally recognized leader 1-table, 2-charis, 2-laptops, 2 small monitors, in health care quality. Our patients and physi- 1small stand by The Medicines Company. cians have access to the latest technology and medical treatments available. Aurora offers a multitude of practice options from small town, to large city to somewhere in between. EXHIBITOR PRODUCT & RESOURCE SECTION StrokeNews 9

iRhythm Technologies, Multigon Industries, Philips InnerCool 519 RIMED LTD 423 VasSol, Inc. 516 Inc. 334 Inc. 311 6740 Top Gun St. 25 HACHAROSHET St. Telespecialists, LLC 219 348 Lathrop Ave. 650 Townsend St. 525 Executive Blvd. San Diego, CA 92121 INDUSTRIAL PARK RAANANA 43656 8965 College Parkway River Forest, IL 60305 Suite 380 Elmsford, NY 10523 (858) 713-9524 Israel Suite 2476 (708) 366-7000 San Francisco, CA 94103 (914) 376-5200 WEB: philips.com/innercool (646) 205-2186 Fort Myers, FL 33919 [email protected] (888) 693-2401 [email protected] Philips InnerCool is the only company to [email protected] (800) 998-8556 WEB: vassolinc.com [email protected] WEB: multigon.com provide a complete continuum of temperature WEB: rimed.com WEB: tele-specialists.com VasSol develops and markets the NOVA WEB: irhythmtech.com Multigon booth 311 showing the bilateral all management therapy products with innovative Rimed is a manufacturer of Transcranial doppler Telespecialists provides neurology and ICU software for Quantitative Magnetic Resonance Continuous 7-to-14 day ambulatory ECG moni- digital ROBOTOC2MD Transcranial Doppler endovascular and surface-based systems. The systems (TCD). These systems measure non- telemedicine services. Angiography (qMRA). The NOVA-Neuro toring of patients with suspected arrhythmias with ROBOTIC HEADBAND. Continuous moni- RTx Endovascular and the STx Surface Cool- invasively the blood flow velocity in the main application provides complete evaluation of improves diagnosis of arrhythmias, including toring for hours without headband adjustment. ing and Warming Systems allow hospitals to arteries in the brain. Rimed was established volumetric blood flow rates and flow direction AF. The ZIO® Service includes a small, water- CO2 monitoring, vasospasm monitoring,emboli utilize technologies with different performance in 1982. Since then the company has been within the circle of Willis. Come visit and see resistant, wire-free ZIO Patch for the patient, detection and tracking,vasoreactivity, autonomic characteristics to address all their cooling and developing, manufacturing and exporting 7 Tenet South Florida — what quantitative vessel measurement can add and the ZIO Patch Report, with comprehensive testing. Ideal for clinical exams, intraoperative warming needs. generations of non-invasive Transcranial Doppler Advanced Neuroscience to the hemodynamic assessment of the cerebral and easy-to-read preliminary findings reviewed monitoring, sonothrombolysis,long term moni- systems over 40 countries worldwide. Network 336 vasculature. by certified cardiovascular technicians for toring, pfo,sickle cell management, statistical Quintiles 337 9960 Central Park Blvd., N. data reduction. Clinical training included. 201 Broadway Fifth Floor Wolters Kluwer Health 427 interpretation by physicians. Siemens 642 Suite 400 Cambridge, MA 02139 51 Valley Stream Parkway Two Commerce Sq Boca Raton, FL 33498 National Insitute of (888) 526-6700 2001 Market St., Third Floor Jan Medical Inc. 111 J12 (561) 288-5511 [email protected] 67 E. Evelyn Ave., Suite 6 Neurological Disorders Malvern, PA 19355 [email protected] Philadelphia, PA 19103 WEB: quintiles.com Mountain View, CA 94041 and Stroke (NINDS) 143 web: usa.healthcare.siemens.com WEB: tenetfloridaphysicianservices.com (215) 521-8300 Outcome, a Quintiles Company, is a leading (650) 316-8811 31 Center Drive, Room 8A07 Siemens Healthcare provides The Tenet Florida Advanced Neuroscience [email protected] provider of web-based quality measurement [email protected] Bethesda, MD 20892 innovative solutions for the diagnosis, treatment, Network includes over 40 physicians, 10 award WEB: lww.com systems for quality-improvement (QI), pay-for WEB: janmedical.com (301) 496-5751 intervention and therapy of diseases affecting winning hospitals and multiple full service Lippincott Williams & Wilkins, a Wolters Kluwer performance, reimbursement, accreditation, and Jan Medical has developed the first and only [email protected] our clinican’s patients and their families. outpatient centers across Miami-Dade, Broward Health company, is the proud publisher of 11 certification programs, dedicated to providing portable brain sensing device designed to WEB: ninds.nih.gov and Palm Beach Counties. Our team provides of the American Heart Association journals and hospitals and physician practices with solutions enable timely determination of ischemic stroke. The National Institute of Neurological Disorders Society of comprehensive neurological & ancillary services The AHA Clinical Cardiac Consult. We proudly and resources to ensure continuous quality A determination can be made in minutes. The and Stroke provides International Stroke Confer- and features some of the leading neurologists in offer a full range of specialized books, journals, improvement in patient care. NeuroInterventional Nautilus NeuroWave™ is also being evaluated ence members with information about available S. Florida. To learn more visit www.tenetphysi- and electronic media to meet your information Surgery 417 needs. for possible reliable detection of traumatic brain research support and funding mechanisms, 3975 Fair Ridge Drive, Suite 200 North cians.com injuries, including concussions. as well as free publications for patients and Fairfax, VA 22033 their families on stroke and other neurological REACH Health 248 Toshiba America World Stroke Janssen 10745 Westside Way Organization 225 disorders. NINDS staff will be available to assist Spectrum Health Medical Systems, Inc. 522 Pharmaceuticals, Inc. 229 you. Printed material is available. Alpharetta, GA 30009 1-3 Chantepoulet Medical Group 214 2441 Michelle Drive 1000 Route 202 (855) 641-8911 Tustin, CA 92780 Geneva 01211 Switzerland [email protected] 100 Michigan St. N.E. Raritan, NJ 08869 National Stroke (714) 730-5000 (122) 906-9149 WEB: reachhealth.com MC 521 908-218-6000 Association 244 WEB: medical.toshiba.com [email protected] REACH Health powers many of the nation’s [email protected] 9707 E. Easter Lane Grand Rapids, MI 49503 An innovator in medical imaging technology, WEB: world-stroke.org largest and most successful telemedicine net- [email protected] The World Stroke Organization (WSO) is the web: janssenpharmaceuticalsinc.com Centennial, CO 80112 Toshiba America Medical Systems markets, works, helping health systems achieve measur- Janssen Pharmaceuticals, Inc. provides (800) 787-6537 WEB: shmg.org sells, distributes and services diagnostic only official WHO affiliated NGO dedicated to able improvements in clinical, operational and medicines in several therapeutic areas, including [email protected] Spectrum Health Medical Group (SHMG) was imaging systems throughout the U.S. Toshiba the global fight against stroke. Our mission is to financial performance. REACH Health enterprise ADHD, mental health, general medicine, neurol- WEB: stroke.org formed in October, 2008 to complement the is committed to providing customers with the reduce the burden of stroke across the world telemedicine software combines real-time au- ogy including Alzheimer’s disease, pain manage- National Stroke Association’s mission is to other elements of its system: Spectrum Health patient-focused technology and optimum sys- and improve the quality of life of stroke survivors dio/video technology with patient data, clinical reduce the incidence and impact of stroke. The Hospital Group and Priority Health. SHMG has tem performance needed to succeed in today’s though education, public awareness and patient ment, cardiovascular, and women’s health. workflow and documentation to overcome the organization offers the latest in multi-format dual purposes: Provide better patient care, in healthcare marketplace. support. traditional obstacles of time and distance. The Joint Commission 246 accredited professional education and Stroke terms of outcomes and experiences. Provide Center NetworkTM, a membership for stroke physicians with the greatest possible personal UMiami Gordon ZOLL Medical One Renaissance Blvd. and professional satisfaction. Corporation 410 Oakbrook Terrace, IL 60181 centers and rehabilitation facilities that includes Center for Research free patient materials, including StrokeSmartTM Restaurant 253 269 Mill Road (630) 792-5291 in Medical Education 319 magazine. Visit www.stroke.org for more Stryker Neurovascular 511 [email protected] P.O. Box 016960 (D-41) Chelmsford, MA 01824 information. Retreat & Refresh 47900 Bayside Parkway (978) 421-9655 WEB: jointcommission.org Fremont, CA 94538 1120 N.W. 14th St. Joint Commission Certification for Primary Stroke Camp 318 [email protected] (510) 413-2500 First Floor - 33136 Stroke Centers provides a comprehensive NET SMART 326 425 W. Giles Lane WEB: zoll.com WEB: stryker.com/neurovascular Miami, FL 33101 evaluation of this patient population, with an as- 16410 E. Emerald Drive Peoria, IL 61614 ZOLL Medical Corporation, a leader in medical Stryker Neurovascular is com- (305) 243-6491 sessment of specific clinical practice guidelines Suite 201 (866) 688-5450 products and software solutions, offers Intra- mitted to Complete Stroke Care™ through in- [email protected] and performance outcomes measurement Fountain Hills, AZ 85268 [email protected] vascular Temperature Management (IVTM™) novative products, technologies and services for WEB: gcrme.med.miami.edu requirements. Over 900 hospitals have certified (480) 600-9383 WEB: strokecamp.org solutions, which provide healthcare profes- ischemic and hemorrhagic stroke. By advancing The University of Miami Gordon Center is the their primary stroke programs. Certification of [email protected] Retreat & Refresh Stroke Camp (RRSC) sionals with the power and control needed to the practice of less-invasive medicine, providing developer of Advanced Stroke Life Support®, your stroke program demonstrates excellence in WEB: learnstroke.com provides a national network of weekend retreats rapidly, safely, and more effectively manage the healthcare professionals more endovascular a hands-on 8-hour curriculum for EMS person- fostering better outcomes. NET SMART offers evidence-based acute for stroke survivors and caregivers. RRSC is core body temperature of critically ill or surgical solutions and promoting clinical education and nel, nurses, and physicians that satisfies Joint stroke education for nurses, PAs, APNs, and committed to providing stroke awareness and patients with warming and cooling applications. support, Stryker Neurovascular is dedicated to Commission educational requirements for stroke physicians, with on-line accessible programs education through: Strike Out Stroke events The Medicines helping deliver better patient outcomes. centers. Its unique neurologic assessment complimented by clinical skills exercises that with major and minor league baseball teams, the Company 414 tool—the MEND Exam—is ideal for prehospital 8 Sylvan Way reinforce learning through application of new “Now What?” DVD for survivors/caregivers, and MEGA Brain exhibits. and hospital use. Parsippany, NJ 07054 information. To date, NET SMART graduates hold a 100% pass rate on the NVRN, SCRN, and (973) 290-6000 ANVP board certification exams. WEB: themedicinescompany.com The Medicines Company’s purpose is to save lives, alleviate suffering, and contribute to NeurOptics 210 the economics of healthcare by focusing on 2082 Michelson Drive, Suite 450 3,000 leading acute/intensive care hospitals Irvine, CA 92612 worldwide. Its vision is to be a leading provider (949) 250-9792 of solutions in three areas: acute cardiovascular [email protected] care, surgery/perioperative care, and serious WEB: NeurOptics.com infectious disease care. About NeurOptics Based in Irvine, California, NeurOptics, Inc., provides devices that collect EXHIBIT HALL MAP Medtronic, Inc. 528 and process information from the human eye to 710 Medtronic Parkway facilitate medical decision-making and enable Minneapolis, MN 55432 clinical research. The company offers the NPi™- 100 Pupillometer for Critical Care, as (763) 514-4000 well as pupillometers for Research and Oph- WEB: medtronic.com thalmology. For more information, visit www. At Medtronic, we’re committed to Innovating NeurOptics.com. for Life by identifying unmet medical needs RESTAURANT segments and finding a solution using medical technology. Visit booth #528 to see how you NourishCare Pureed can reveal atrial fibrillation in your cryptogenic Meals 620 stroke patients. 3210 S.E. 72nd St. Ankeny, IA 50021 MEYTEC Telemedicine (855) 431-6667 549 B648 B655 Systems 335 [email protected] Akazienstrasse 13 WEB: purfoods.com Public Werneuchen OT Seefeld, Produced by family-owned PurFoods, Nourish- Care Pureed Meals are developed by chefs and Service AHA/ASA Brandenburg 16356 dietitians to be nutritionally complete and are 644 Germany designed to look appealing and taste delicious. HeadQuarters [email protected] WEB: vimed.de Ornim Medical LTD 526 543 642 MEYTEC is a specialist healthcare company 15 Atir Yeda St. that produces propriety telemedicine solu- Kfar Saba 4464312 Israel tions under the VIMED® brand for medical 241 (972) 892-8280 establishments around the world. MEYTEC has [email protected] developed pioneering bespoke tele-medical and WEB: ornim.com pre-hospital solutions such as STEMO for stroke H. Ornim specializes in research, development, and other medical specialities, using the digital and distribution of non-invasive patient monitors Lundbeck Covidien transmission of medical data, audio-video and 237 336 337 InTouch specializing in the field of tissue and cerebral radiology images. A/S Health blood flow. 135 235 334 335 434 435 535 MicroVention, Inc. 543 Penumbra, Inc. 325 1311 Valencia Ave. 1351 Harbor Bay Parkway Tustin , CA 92780 Alameda, CA 94502 (714) 247-8100 INTERNATIONAL STROKE CONFERENCE (510) 748-3200 [email protected] [email protected] WEB: microvention.com WEB: penumbrainc.com MicroVention develops innovative neuroendo-

Penumbra, Inc. is a medical device company PLENARY vascular technologies and devices to include, POSTERS that strives to deliver clinically beneficial de- 229 528 the MicroPlex® Coil Systems, the HydroCoil® vices to patients suffering from stroke and Embolic Systems, featuring the V-Trak® Delivery Boehringer Penumbra, Charging vascular disease. We are committed to the System and a full line of access products Ingelheim 227 Inc. design, development and clinical application of 326 427 526 Station including the Traxcess® hydrophilic coated innovative therapies in the neurovascular space. guidewires, the Chaperon® Guiding Catheter System, the Headway® Microcatheter and the 125 225 324 325 425 524 525 ScepterTM C/XC Occlusion Balloon Catheter Perimed Inc. 419 44 W. Lancaster Ave. Motorika USA 217 Suite 220 223 320 423 522 4255 A Praytor Way Ardmore, PA 19003 Mobile applications are available at Trussville, AL 35173 (484) 416-3561 121 220 420 521 620 strokeconference.org/mobile. (205) 655-6591 [email protected] [email protected] WEB: perimed-instruments.com New and imprimprovedoved MobMobileile MeetMeetinging GuidGuidee ApApp:p: Perimed designs and manufactures equipment 119 218 219 318 319 418 419 518 519 618 WEB: motorika.com AHA SScientificcientific ConferencesConferences ReoGo by Motorika is the world’s most for microcirculatory measurement and diagno- advanced robotic system for upper limb therapy, sis. The new PeriFlux 6000 is a technological 217 316 417 516 517 616 designed to facilitate three-dimensional repeti- leap for transcutaneous oxygen measurement tive arm movements through the use of a fully (TCOM), combining a touchscreen interface with motorized robotic arm. The system is suited a host of new features and HIPAA compliancy. 115 214 315 414 514 for a variety of patients in all stages of stroke The PeriFlux recovery, offering five modes of assistance. AHA 113 212 313 412 512 Stryker Science Neurovascular News Download the meeting 111 210 211 311 410 411 510 511 guide app now! REGISTRATION

©2014,4 American Hearrt As ssocisoc atiotioon 1/14DSD 7640 10 STROKENEWS Thursday, February 13, 2014 strokeconference.org

HYPOTHERMIA use of hypothermia in ischemic stroke,” Hemmen Center at Caja del Seguro Social Hospital in Therapeutic hypothermia generally in- continued from page 1 said. “We have a therapy that works in global hy- Panama, will describe therapeutic hypothermia volves either cooling pads on the skin or cath- poxia. Hypothermia is effective in cardiac arrest for acute spinal cord injury and diffuse axonal eters to remove excess energy. These devices Many neurologists attending ISC 2014 may not in adults and in asphyxia in babies, and it should injury. work, but the clinical application of hypother- be aware of the shift in treatment that has already work in focal hypoxia as well. Stroke, in essence, Traumatic brain and spinal cord injuries are mia is cumbersome. Even minor shivering can occurred in cardiac arrest, neonatal asphyxia and is a focal area of hypoperfusion just as cardiac the newest areas of research in neuroprotective generate enough energy and heat to overcome other conditions.” arrest is a global hypoperfusion in the brain.” hypothermia. Work is progressing on plans for the cooling effect of current technology. Hemmen will be co-moderator of “Neuro- Midori Yenari, MD, professor of neurology a clinical study of therapeutic hypothermia in “The exciting news is the possibility of us- protection through Therapeutic Hypother- at the University of California in San Francis- traumatic spinal cord injury. ing pharmacologic agents to induce hypother- mia” at 8:40–10:10 a.m. Thursday in Room co, will explore the neuroprotective mecha- Hypothermia offers an elegant therapeutic mia,” Hemmen said. 30A-D. His co-moderator is Patrick Lyden, nisms of hypothermia in current therapeutic solution for neuroprotection, but the practice Shan Ping Yu, PhD, professor of anesthesi- MD, professor and chair of neurology and uses as well as in ischemic stroke. can be complex. The problem with hypother- ology at Emory University School of Medi- director of the stroke program at Cedars-Sinai The next presentation will discuss the latest mia is cooling the core temperature without cine in Atlanta, will explore the modality of Medical Center in Los Angeles. work on hypothermia in ischemic stroke. inducing other neurological problems, shiver- pharmacologic hypothermia to treat ischemic “We want to highlight the ongoing research Guadalupe Argelis Castillo-Abrego, MD, ing and associated medical complications, stroke. in Europe and in North America on testing the medical director of the Comprehensive Stroke Hemmen said. Jesper Petersson, PhD, director of research and education in neurology at Malmö Uni- versity Hospital, Lund University, in Sweden, will explore the overall feasibility of hypo- thermia. “This will be an exciting introduction to concepts that could change the way we deal with stroke as dramatically as hypothermia is changing the way our colleagues deal with cardiac arrest,” Hemmen said.

Session at-a-Glance Neuroprotection through Therapeutic Hypothermia

Thursday, 8:40–10:10 a.m. Ballroom 30A-D

Co-moderators: Thomas Hemmen, MD, PhD, and Patrick Lyden, MD

Poster Tours, Sessions continue today

PALLIATIVE CARE continued from page 1

thorough exploration with patients and caregivers. Pain is a common symptom of stroke that doesn’t always receive the attention it deserves. The initial step is to identify the source of pain, which can be muscu- loskeletal, neurogenic or a combination. “The whole idea behind palliative care is to identify symptoms that are making the course of care more diffi cult for the patient and deal with the symptoms to the extent possible,” Zorowitz said. “And if this is end- of-life care, we need to prevent and relieve suffering as much as possible so that patients can have the best possible quality of life in whatever time remains.” Quality of life can be a controversial area, he said. Medical evidence may suggest that it’s time to withdraw care, but family members may want to press on. “Those kinds of attitudes can make a huge difference to the patient,” Zorowitz said. “The patient could be suffering for a long time and maybe unnecessarily. It becomes our job to talk with patients and families about the risks and the benefi ts of continuing treatment and to come to a consensus about what is best for the pa- tient. Quality of life and the importance of quality of life really comes down to the values and preferences of the patient and the caregivers. We have to make sure they have all the information needed to make their decision.” strokeconference.org Thursday, February 13, 2014 STROKENEWS 11

Follow Stroke on Twitter Regular Poster Use Twitter to tweet your questions/ Sessions comments or talk about what is happening at ISC 2014. Use hashtag: #ISC14. 6:15–6:45 p.m. Posters T P1–T P368 These posters are not included in the 5:15 p.m. Professor-Led Poster Tour Session at left. Professor-Led 1. Acute Endovascular Treatment Posters II Poster Tours 2. Acute Neuroimaging Posters II 3. Acute Nonendovascular Treatment 5:15–6:15 p.m. Posters II Posters T MP1–T MP120 4. Basic and Preclinical Neuroscience of 1. Acute Endovascular Treatment Moder- Stroke Recovery Posters II ated Poster Tour 5. Cerebral Large Artery Disease Posters II 2. Acute Nonendovascular Treatment 6. Clinical Rehabilitation and Recovery Moderated Poster Tour Posters II 3. Cerebral Large Artery Disease Moder- 7. Community/Risk Factors Posters II Poster Tours, Sessions continue today ated Poster Tour 8. Diagnosis of Stroke Etiology Posters II 4. Clinical Rehabilitation and Recovery 9. Emergency Care/Systems Posters II SC 2014 offers two types of poster sessions: During the Regular Poster Sessions, Moderated Poster Tour 10. Experimental Mechanisms and Models professor-led poster tours and one-on-one poster presenters will be at their posters 5. Emergency Care/Systems Moderated Posters II individual Q&A poster presentations. for informal Q&As with attendees from Poster Tour 11. Intracerebral Hemorrhage Posters II Choose from 10 Professor-Led Poster 6:15 to 6:45 p.m. Thursday in Hall G. 6. Community/Risk Factors Moderated 12. Nursing Posters II ITours from 5:15 to 6:15 p.m. Thursday in These one-on-one posters are not a part Poster Tour II 13. Outcomes, Quality and Health Services Hall G. Expert moderators will lead these of the earlier Professor-Led Poster Tours. 7. In-hospital Treatment Moderated Poster Research Posters II tours, which are organized by category; they To see the posters featured in Thursday’s Tour 14. Pediatric Stroke Posters II provide a short presentation and Q&A with Regular Poster Sessions, go to page 79 of 8. Outcomes, Quality and Health Services 15. Preventive Strategies Posters II each of the poster authors in that section. To the Poster Abstracts section of the Final Research Moderated Poster Tour II 16. SAH and Other Neurocritical Manage- take part, simply review the Poster Abstracts Program. 9. Preventive Strategies Moderated Poster ment Posters II section of the Final Program (page 72). Decide Posters also will be available for view- Tour 17. Vascular Cognitive Impairment Posters which section/category of posters you would ing in the Poster Hall (Hall G) from 8 a.m. 10. Vascular Biology in Health and Disease II like to attend. Then, at 5:10 p.m., arrive at the to 6:45 p.m. Thursday. and Vascular Cognitive Impairment 18. Vascular Malformations Posters II correspondingly numbered “Section” sign for Please see page 47 of the Final Pro- Moderated Poster Tour 19. Ongoing Clinical Trials Posters II your selected section/category. gram for the Poster Hall map.

ISC 2015 award nominations JAHA now indexed by Thomson Reuters (formerly ISI) AHA Members: Submit your nominations for the ISC 2015 Feinberg, Willis and AHA — Journal of the American reuse of, all published articles. • Articles are posted online within four Sherman Awards: Heart Association is now indexed This year, JAHA is not only leading the weeks of acceptance, after payment of • Nomination Period Opened: Wednesday, in the Thomson Reuters (formerly Open Access movement in its fi eld, but the Article Publication Charge. As an Feb 12, 2014 ISI) Science Citation Index remains vigilant and committed to: Open Access journal, the payment of an • Nomination Period Closes: Wednesday, ExpandedJ and will receive an Impact Factor • Quality Science: Article Publication July 9, 2014 in 2014. This is recognition of the stature JAHA underwent Charge is Go to strokeconference.org/ of the journal and will make publication in a rigorous required prior to awardsandlectures for more information. JAHA more valuable to authors by further evaluation publication. AHA/ enhancing visibility and discoverability of of published ASA members all the articles published. content before are eligible for Coverage of JAHA will include all being accepted discounted Article published content beginning with Volume by Thomson Publication Abstract categories 1, 2012. Reuters. Charges. • Acute Endovascular Treatment Representing all 16 scientifi c councils, • Compliance: • JAHA offers authors • Acute Neuroimaging JAHA is the voice of the entire American JAHA became the ability to present • Acute Nonendovascular Treatment Heart Association and American Stroke fully compliant all aspects of their • Aneurysm Association. The journal’s mission is to with new work. There are no • Basic and Preclinical Neuroscience of provide a holistic approach to publishing mandates restrictions on article Stroke Recovery that offers every AHA/ASA member the from Research length and there is • Cerebral Large Artery Disease opportunity to share unique interests across Councils UK and unlimited use of color • Clinical Rehabilitation and Recovery all cardiovascular and cerebrovascular Wellcome Trust. images and video. • Community/Risk Factors fi elds. • Expanded Reach: • Immediately on • Diagnosis of Stroke Etiology In less than two years, JAHA has Articles are now publication, JAHA • Emergency Care/Systems accelerated scientifi c discovery and automatically content is avail- • Experimental Mechanisms and Models enriched education by providing free online deposited able in MEDLINE®/ • In-hospital Treatment access to, and unrestricted noncommercial in PubMed Central (now PMC) on PubMed®/Index Medicus and PMC, the • Intracerebral Hemorrhage publication as required by the National free full-text archive of PubMed, as well • Nursing Representing all 16 scientifi c Institutes of Health, Wellcome Trust and as 17 additional databases. • Outcomes, Quality and Health Services other funding agency mandates. This • An iPad/smartphone app is available Research councils, JAHA is the voice benefi ts authors and readers alike. for free to download providing any- • Pediatric Stroke of the entire American Heart time access to JAHA articles. • Preventive Strategies Other highlights and facts • SAH and Other Neurocritical Association and American about JAHA’s progress You can pick up a free JAHA Management Stroke Association. • Original research article submissions booklet with featured articles, • Vascular Biology in Health and Disease have increased by 68 percent from fi scal information for authors, and more at • Vascular Cognitive Impairment year 2011–2012 to fi scal year 2012–2013. AHA/ASA Head Quarters, booth 241. • Vascular Malformations • Median time from submission to fi rst Visit online at jaha.ahajournals. • Ongoing Clinical Trials decision is 19.5 days. org. PAID ADVERTISEMENT

FREE

Stroke

An American Heart Association | American Stroke Association Journal

Stroke offers free, bimonthly webinars―a valuable educational resource to the stroke community for enhancing knowledge about recent developments in this evolving field.

Learn about upcoming topics and presenters, register, and access archived webinars today—visit:

http://stroke.ahajournals.org/site/misc/Stroke_Webinars.xhtml

Don’t miss the next webinar offered in the series!